Express News | Nurix Therapeutics Presents Preclinical Data From Two Autoimmune and Inflammatory Disease Programs, Nx-5948 and Gs-6791, at Acr Convergence 2024

ReutersNov 17 10:30 ET

Nurix Therapeutics Down Over 10%, on Pace for Largest Percent Decrease Since October 2023 -- Data Talk

Dow JonesNov 15 13:52 ET

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 25% Price Boost Is Out Of Tune With Revenues

Simply Wall StNov 7 07:46 ET

Needham Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $29

Moomoo NewsNov 6 06:33 ET · Ratings

Nurix Therapeutics Price Target Maintained With a $29.00/Share by Needham

Dow JonesNov 6 06:19 ET · Ratings

Promising Efficacy and Safety of Nurix Therapeutics' NX-5948 Justifies Buy Rating

TipRanksNov 6 06:15 ET · Ratings